ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues

26 August 2021  ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments  Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials